Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025

Carisma Therapeutics Inc.

2023-Q3 EPS reported -$2.11 revenue$10,630,000

Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.
Cash, cash equivalents and marketable securities of $94.1M as of Sept 30, 2023.
R&D expenses $19.6M, up $4.0M YoY, driven by CT-0525 preclinical costs.
Selected clinical candidate for CT-1119 (anti-mesothelin CAR-Monocyte); IND targeted for 2025.
Updated Phase 1 data for CT-0508 shows safety and biomarker correlation with stable disease.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Carisma Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2.

Period: the quarter ended September 30, 2023
Net income: Net loss was $21.4 million for the third quarter of 2023, compared to net loss of $18.3 million for the same period in 2
Result: reported results

Exact text from the filing

Carisma Therapeutics Inc. (the "Company") announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.